Disease or SyndromeENTITYFunctional Concept FDA delays decision date on Cytokinetics’ heart drug to year-end in unusual safety program back-and-forth 1 week ago talkbio0Tagged Cytokinetics, Deferred, Evaluation, Extension, Hypertrophic obstructive cardiomyopathy, Mitigation Strategy, oHCM, PDUFA, Regulatory Setback, REMS, Risk, United States Food and Drug Administration FDA Delays Cytokinetics' Heart Drug Decision to December 2025 Sources: